Valuation: Rezolute, Inc.

Market Cap 38Cr 34Cr 31Cr 29Cr 54Cr 3.59TCr 56Cr 377.25Cr 150.43Cr 1.92TCr 143.32Cr 140.24Cr 6.05TCr P/E 2027 *
-5.15x
P/E 2028 * -7.04x
Enterprise Value 38Cr 34Cr 31Cr 29Cr 54Cr 3.59TCr 56Cr 377.25Cr 150.43Cr 1.92TCr 143.32Cr 140.24Cr 6.05TCr EV / Sales 2027 *
182x
EV / Sales 2028 * 7.06x
Free-Float
89.97%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Rezolute, Inc.

1 day+1.10%
1 week-5.70%
Current month-5.70%
1 month-13.77%
3 months-20.74%
6 months+18.63%
Current year+57.84%
1 week 3.56
Extreme 3.5635
4.34
1 month 3.37
Extreme 3.37
4.91
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
70
Manager TitleAgeSince
Chief Executive Officer 59 30/01/2013
Director of Finance/CFO 53 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 59 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 70 10/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Tax

Executive/Senior Manager

-2,267 0.0024%
02/07/26 Tax

Chief Technology Officer

-3,062 0.0035%
02/07/26 Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%-5.70%-61.20%+293.35% 38Cr
-4.83%+2.88%+55.87%+69.12% 6.94TCr
+0.02%+1.07%+10.63%+76.66% 5.72TCr
-1.34%+2.98%+24.79%+100.18% 5.76TCr
+2.59%+1.59%+28.80%+36.89% 4.37TCr
+5.59%+10.57%+23.20%+108.76% 4.4TCr
+8.31%+0.79%+214.14%+795.17% 3.81TCr
-1.86%+11.46%+26.67%+61.40% 3.63TCr
-2.97%-9.84%+88.86%+76.17% 3.26TCr
-2.18%+5.68%+36.21%-0.69% 2.55TCr
Average +0.46%+0.85%+44.80%+161.70% 4.05TCr
Weighted average by Cap. +0.13%+2.42%+52.16%+139.43%

Financials

2027 *2028 *
Net sales 20.95L 18.79L 17.17L 15.67L 29.53L 20Cr 30.46L 2.07Cr 82.52L 11Cr 78.62L 76.94L 33Cr 5.41Cr 4.85Cr 4.43Cr 4.05Cr 7.63Cr 508.45Cr 7.87Cr 53Cr 21Cr 271.3Cr 20Cr 20Cr 856.47Cr
Net income -7.95Cr -7.13Cr -6.52Cr -5.95Cr -11Cr -747.19Cr -12Cr -79Cr -31Cr -398.68Cr -30Cr -29Cr -1.26TCr -5.99Cr -5.38Cr -4.91Cr -4.48Cr -8.45Cr -563.37Cr -8.72Cr -59Cr -24Cr -300.6Cr -22Cr -22Cr -948.97Cr
Net Debt - -
Projected Income Statement - Annual - Rezolute, Inc.
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
58
Date Price Change Volume
07/26/07 $3.725 +2.34% 6,87,970
05/26/05 $3.640 -8.08% 12,28,076
04/26/04 $3.960 -1.25% 10,74,154
03/26/03 $4.010 +3.35% 9,19,347
02/26/02 $3.880 -1.77% 8,45,175
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rezolute, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.640USD
Average target price
9.800USD
Spread / Average Target
+169.23%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rezolute, Inc.
  1. Stock Market
  2. Stocks
  3. RZLT Stock